Table 1.
Patient ID | scRNA-Seq | Amplicon-Based NGS from Bulk DNA | Common CDR3 | ||||
---|---|---|---|---|---|---|---|
IGHV | IGHJ | Proportion | IGHV | IGHJ | Proportion | ||
PLC-01 | IGHV3-48 | IGHJ4 | 92.90% | IGHV3-30*09 | IGHJ4*02 | 67.55% | CARDSYEDYVYW |
PLC-02 | IGHV3-21 | IGHJ4 | 97.93% | IGHV3-21*01 | IGHJ4*02 | 74.39% | CARYQLDAVAGKWGHYFDYW |
PLC-03 | IGHV3-43 | IGHJ5 | 97.77% | IGHV3-9*01 | IGHJ4*02 | 66.23% | CAKARLPLVGGLDSW |
PLC-05 | IGHV3-43 | IGHJ6 | 49.79% | IGHV3-9*01 | IGHJ6*02 | 13.62% | CTRVIGSGASCYDCYYHGMDVW |
PLC-06 | IGHV3-53 | IGHJ5 | 87.91% | IGHV3-53*01 | IGHJ4*02 | 57.58% | CARGLTAPGFPLDSW |
PLC-07 | IGHV3-23 | IGHJ6 | 65.26% | IGHV3-23*01 | IGHJ6*01 | 56.92% | CAKGRADCTDGVCYRRYGMDVW |
PLC-08 | IGHV3-43 | IGHJ4 | 99.44% | IGHV3-43*01 | IGHJ4*02 | 81.44% | CVKGQGGYTYGGFDCW |
PLC-10 | IGHV5-51 | IGHJ4 | 77.63% | IGHV5-51*01 | IGHJ4*02 | 57.39% | CARTNWPYYFDHW |
PLC-12 | IGHV3-43 | IGHJ4 | 93.73% | IGHV3-9*01 | IGHJ4*02 | 62.86% | CARDRYQLIIYYFDRW |
PLC-15 | IGHV3-43 | IGHJ4 | 98.97% | IGHV3-9*01 | IGHJ4*02 | 32.77% | CAKDVRYGYGSTQSAGFDYW |
PLC-17 | IGHV4-39 | IGHJ4 | 95.53% | IGHV4-39*07 | IGHJ4*02 | 22.10% | CARDKTTMTFSSPIFDYW |
PLC-18 | IGHV2-5 | IGHJ1 | 95.78% | IGHV2-5*02 | IGHJ1*01 | 56.58% | CAHSGSMWSGYAGTEYFQHW |
PLC-19 | IGHV4-59 | IGHJ4 | 67.50% | IGHV4-59*01 | IGHJ4*02 | 21.08% | CARAGDYDLLLLDYW |
PLC-21 | IGHV5-51 | IGHJ6 | 80.02% | IGHV5-51*03 | IGHJ6*03 | 56.06% | CARLPQGGYYYMDVW |
PLC-22 | IGHV3-53 | IGHJ5 | 85.10% | IGHV3-53*01 | IGHJ4*02 | 77.01% | CARGLTAPGFPLDSW |
PLC-23 | IGHV3-33 | IGHJ1 | 56.11% | IGHV3-30-3*02 | IGHJ1*01 | 61.13% | CAFAIGADGEYFQHW |
PLC-24 | IGHV2-70 | IGHJ4 | 69.68% | IGHV2-70*01 | IGHJ4*02 | 40.67% | CARGASETQVAMSTAELYFFDSW |